

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERC United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

DATE MAILED: 02/24/2005

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/608,105	06/30/2003	John P. Tarlano		1055	
7590 02/24/2005		EXAMINER			
John P. Tarlano 6912 Sydenstricker Road			ARTMAN, THOMAS R		
Springfield, VA 22152			ART UNIT	PAPER NUMBER	
			2882		

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	10/608,105	TARLANO, JOHN P.			
Office Action Summary	Examiner	Art Unit			
	Thomas R Artman	2882			
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the c	orrespondence address			
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days fill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE!	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 07 Fe	ebruary 2005.				
2a)⊠ This action is FINAL . 2b)☐ This	action is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	33 O.G. 213.			
Disposition of Claims					
4)⊠ Claim(s) <u>1 and 2</u> is/are pending in the applicati	on.				
4a) Of the above claim(s) is/are withdray	4a) Of the above claim(s) is/are withdrawn from consideration.				
5)⊠ Claim(s) <u>2</u> is/are allowed.					
6)⊠ Claim(s) <u>1</u> is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/or	r election requirement.				
Application Papers					
9) The specification is objected to by the Examine	r.				
10)⊠ The drawing(s) filed on <u>30 June 2003</u> is/are: a)⊠ accepted or b)☐ objected to by the Examiner.					
Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).			
Replacement drawing sheet(s) including the correct					
11) ☐ The oath or declaration is objected to by the Ex	aminer. Note the attached Office	Action or form PTO-152.			
Priority under 35 U.S.C. § 119		:			
 12) ☐ Acknowledgment is made of a claim for foreign a) ☐ All b) ☐ Some * c) ☐ None of: 1. ☐ Certified copies of the priority documents 		-(d) or (f).			
2. Certified copies of the priority documents		on No			
3. Copies of the certified copies of the prior	• •				
application from the International Bureau	•				
* See the attached detailed Office action for a list		ed.			
Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Da	ate Patent Application (PTO-152)			
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	6) Other:				

DETAILED ACTION

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claim 1 is provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1 and 2 of copending Application No. 10/445614. The conflicting claims are not identical, since claim 1 discloses every limitation except for using the sources to produce a series of X-ray bursts. However, they are not patentably distinct from each other because the teachings of the method of claim 2 of the copending application specifically use the sources for providing a series of X-ray bursts in order to selectively destroy harmful life forms in a human. Therefore, it would have been obvious to modify the present invention to provide a series of X-ray bursts in order to provide a useful service.

This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

Allowable Subject Matter

Claim 2 is allowed.

The following is a statement of reasons for the indication of allowable subject matter: the prior art of record neither teaches nor reasonably suggests the method of inactivating cancer cells, where at least a sub-sequence of the DNA of cancer cells and the surrounding tissues are removed from the patient and determined, where the sub-sequences of the DNA of the cancer cells are different than the surrounding tissue DNA sub-sequences, and then irradiating the patient with a series of x-ray pulses having a sequence of frequencies that energize the series of bases of the sub-sequence of the DNA of the cancer cells, as required by claim 2.

The best prior art of record, Cyrulnik (US 5,044,006) irradiates the patient in order to sweep the microwave frequencies of the amplitude modulated x-ray beams in order to find the resonant frequency of the amplitude modulation with the DNA of the cancer cells, and then irradiates the patient at that modulation. Govind (US 5,690,109) teaches the practice of using Nuclear Magnetic Resonance (NMR) to find the right combination of magnetic field intensity and radio frequency for amplitude modulation of the magnetic field intensity.

In both prior art references, the resonant frequencies for the amplitude modulation of the radiation of choice is determined without removal of cells from the patient and without determination of at least a portion of a DNA sequence.

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Gordon (US 4,622,952) teaches the practice of using Magnetic Resonance to selectively destroy malignant tissues.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Thomas R Artman whose telephone number is (571) 272-2485. The examiner can normally be reached on 9am - 6:30pm Monday - Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ed Glick can be reached on (571) 272-2490. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Thomas R. Artman Patent Examiner

APA

Craig E. Church Primary Examiner

Crang E Church